Precigen (NASDAQ:PGEN) Reaches New 12-Month High - Should You Buy?

Key Points

• Precigen shares reached a new 52-week high after the company reported Q2 revenue of $54.98 million and EPS of $0.05, significantly exceeding analyst expectations. Revenue surged more than 6,300% year over year.
• PAPZIMEOS is driving growth: The product generated $53.1 million in Q2 revenue, more than double the prior quarter, while patient enrollment surpassed 500. Management expects current resources and product revenue to support cash-flow break-even by the end of 2026.
• Analyst sentiment is mixed but includes an $18 price target from HC Wainwright, while MarketBeat’s consensus rating remains Hold with an average target of $14.50. Heavy options activity and recent insider selling add potential volatility and caution.

Precigen, Inc. (NASDAQ:PGEN - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $7.23 and last traded at $6.89, with a volume of 16909114 shares traded. The stock had previously closed at $6.53.

More Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong Q2 earnings beat: Precigen reported $54.98 million in revenue, far above the roughly $28 million analyst consensus, while earnings were $0.05 per share versus expectations for a loss of approximately $0.01–$0.02. Revenue increased sharply year over year, and the company posted $20.1 million in net income attributable to common shareholders. Precigen Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: PAPZIMEOS momentum is driving the business: PAPZIMEOS generated $53.1 million of Q2 net revenue, more than double the prior quarter. Patient-hub enrollment exceeded 500, and FDA-granted seven-year market exclusivity strengthens the product’s commercial outlook. Management said current resources and product revenue are expected to support cash-flow break-even by the end of 2026. Precigen Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Analyst support remains favorable: HC Wainwright reiterated its Buy rating and $14 price target, well above recent trading levels. The firm’s endorsement reinforced the bullish reaction to the earnings report. HC Wainwright Reiterates Buy Rating for Precigen
• Neutral Sentiment: Unusually heavy options activity suggests increased investor attention and potentially higher near-term volatility, but the report does not establish whether options traders are primarily bullish or bearish. Precigen Target of Unusually Large Options Trading
• Negative Sentiment: Insider selling is a counterpoint: Precigen executives, including the COO, CEO and CFO, have reported stock sales, with no insider purchases cited over the past six months. The latest COO sale was made under a pre-arranged Rule 10b5-1 plan, reducing its informational significance but still presenting a potential overhang. Precigen Insider Selling

Analyst Ratings Changes

A number of research firms have weighed in on PGEN. Weiss Ratings restated a "sell (d-)" rating on shares of Precigen in a research note on Friday, July 17th. HC Wainwright increased their price target on shares of Precigen from $14.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday. Citizens Jmp raised their price target on shares of Precigen from $9.00 to $11.00 and gave the company a "market outperform" rating in a research report on Thursday, May 14th. Wall Street Zen lowered shares of Precigen from a "buy" rating to a "hold" rating in a report on Sunday, May 31st. Finally, Citigroup reaffirmed an "outperform" rating on shares of Precigen in a research report on Thursday, May 14th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $14.50.

Precigen Trading Up 5.5%

The stock has a 50-day simple moving average of $5.12 and a two-hundred day simple moving average of $4.46. The company has a debt-to-equity ratio of 4.62, a quick ratio of 4.12 and a current ratio of 4.82. The firm has a market cap of $2.46 billion, a PE ratio of -6.62 and a beta of 1.02.

Precigen (NASDAQ:PGEN - Get Free Report) last posted its earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.06. The business had revenue of $54.98 million for the quarter, compared to analysts' expectations of $27.98 million. Precigen had a negative net margin of 183.98% and a positive return on equity of 484.64%. The business's quarterly revenue was up 6322.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Precigen, Inc. will post -0.02 EPS for the current year.

Insider Activity at Precigen

In related news, insider Donald P. Lehr sold 29,131 shares of the firm's stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $4.36, for a total value of $127,011.16. Following the sale, the insider owned 755,461 shares in the company, valued at approximately $3,293,809.96. This trade represents a 3.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Rutul R. Shah sold 42,924 shares of Precigen stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $5.85, for a total transaction of $251,105.40. Following the completion of the sale, the chief operating officer directly owned 497,751 shares of the company's stock, valued at approximately $2,911,843.35. This trade represents a 7.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 956,500 shares of company stock worth $5,248,371 in the last three months. 41.40% of the stock is currently owned by company insiders.

Institutional Trading of Precigen

Several large investors have recently modified their holdings of the company. Occam Crest Management LP boosted its position in Precigen by 29.6% in the fourth quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company's stock worth $14,637,000 after purchasing an additional 799,339 shares during the last quarter. KBC Group NV purchased a new stake in shares of Precigen during the 1st quarter valued at about $1,338,000. UBS Group AG increased its position in shares of Precigen by 41.4% during the 4th quarter. UBS Group AG now owns 891,428 shares of the biotechnology company's stock valued at $3,726,000 after purchasing an additional 260,824 shares during the last quarter. Investment Insight Wealth Management LLC bought a new position in shares of Precigen in the 4th quarter worth approximately $443,000. Finally, Impala Asset Management LLC bought a new position in shares of Precigen in the 4th quarter worth approximately $690,000. Institutional investors own 33.51% of the company's stock.

About Precigen

Precigen, Inc NASDAQ: PGEN is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen's approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen's technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source